Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 35.15
(-0.99%)
TWD 35.15
(-0.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 402.69 Million TWD | -18.92% |
| 2022 | 591.56 Million TWD | 43.64% |
| 2021 | 417.82 Million TWD | -0.54% |
| 2020 | 412.99 Million TWD | -7.42% |
| 2019 | 447 Million TWD | 40.66% |
| 2018 | 318.31 Million TWD | -20.16% |
| 2017 | 339.53 Million TWD | -10.7% |
| 2016 | 447.7 Million TWD | 11.92% |
| 2015 | 377.99 Million TWD | 64.25% |
| 2014 | 244.28 Million TWD | 77.88% |
| 2013 | 136.94 Million TWD | -34.77% |
| 2012 | 219.72 Million TWD | 59.61% |
| 2011 | 123.97 Million TWD | 71.19% |
| 2010 | 76.64 Million TWD | -13.26% |
| 2009 | 92.23 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 115.86 Million TWD | 532.9% |
| 2024 Q2 | 101.85 Million TWD | -12.29% |
| 2023 Q4 | 54.32 Million TWD | -51.71% |
| 2023 Q3 | 112.48 Million TWD | -27.23% |
| 2023 FY | - TWD | -18.92% |
| 2023 Q1 | 160.2 Million TWD | -29.72% |
| 2023 Q2 | 154.56 Million TWD | -3.52% |
| 2022 Q1 | 94.83 Million TWD | -1.51% |
| 2022 FY | - TWD | 43.64% |
| 2022 Q4 | 227.95 Million TWD | 65.6% |
| 2022 Q3 | 137.65 Million TWD | 3.1% |
| 2022 Q2 | 133.51 Million TWD | 40.78% |
| 2021 Q4 | 96.29 Million TWD | -7.95% |
| 2021 Q1 | 100.21 Million TWD | -0.58% |
| 2021 Q2 | 112.39 Million TWD | 12.16% |
| 2021 FY | - TWD | -0.54% |
| 2021 Q3 | 104.6 Million TWD | -6.93% |
| 2020 Q3 | 86.06 Million TWD | -16.91% |
| 2020 Q2 | 103.57 Million TWD | -17.36% |
| 2020 Q4 | 100.79 Million TWD | 17.12% |
| 2020 Q1 | 125.32 Million TWD | -11.28% |
| 2020 FY | - TWD | -7.42% |
| 2019 Q4 | 141.25 Million TWD | 15.54% |
| 2019 Q2 | 98.16 Million TWD | 12.3% |
| 2019 Q1 | 87.41 Million TWD | 23.15% |
| 2019 FY | - TWD | 40.66% |
| 2019 Q3 | 122.26 Million TWD | 24.54% |
| 2018 FY | - TWD | -20.16% |
| 2018 Q4 | 70.98 Million TWD | 15.39% |
| 2018 Q3 | 61.51 Million TWD | -35.35% |
| 2018 Q2 | 95.14 Million TWD | 3.84% |
| 2018 Q1 | 91.62 Million TWD | -8.89% |
| 2017 FY | - TWD | -10.7% |
| 2017 Q4 | 100.56 Million TWD | 18.98% |
| 2017 Q3 | 84.52 Million TWD | -11.06% |
| 2017 Q1 | 119.78 Million TWD | 0.28% |
| 2017 Q2 | 95.03 Million TWD | -20.66% |
| 2016 FY | - TWD | 11.92% |
| 2016 Q4 | 119.45 Million TWD | 29.06% |
| 2016 Q3 | 92.55 Million TWD | -19.49% |
| 2016 Q2 | 114.95 Million TWD | -4.88% |
| 2016 Q1 | 120.86 Million TWD | 14.56% |
| 2015 Q2 | 93.69 Million TWD | 9.69% |
| 2015 Q3 | 115.51 Million TWD | 23.3% |
| 2015 Q4 | 105.5 Million TWD | -8.67% |
| 2015 FY | - TWD | 64.25% |
| 2015 Q1 | 85.41 Million TWD | -7.38% |
| 2014 Q3 | 75.83 Million TWD | 82.97% |
| 2014 Q1 | 34.1 Million TWD | -18.33% |
| 2014 FY | - TWD | 77.88% |
| 2014 Q4 | 92.22 Million TWD | 21.61% |
| 2014 Q2 | 41.44 Million TWD | 21.53% |
| 2013 Q2 | 27.64 Million TWD | -14.15% |
| 2013 Q4 | 41.75 Million TWD | 18.14% |
| 2013 FY | - TWD | -34.77% |
| 2013 Q1 | 32.2 Million TWD | -22.45% |
| 2013 Q3 | 35.34 Million TWD | 27.86% |
| 2012 Q1 | 49.42 Million TWD | 48.42% |
| 2012 Q2 | 63.76 Million TWD | 29.01% |
| 2012 FY | - TWD | 59.61% |
| 2012 Q3 | 57.57 Million TWD | -9.7% |
| 2012 Q4 | 41.52 Million TWD | -27.88% |
| 2011 Q2 | 22.91 Million TWD | -47.65% |
| 2011 Q1 | 43.76 Million TWD | 85.5% |
| 2011 Q4 | 33.3 Million TWD | 5.57% |
| 2011 Q3 | 31.54 Million TWD | 37.66% |
| 2011 FY | - TWD | 71.19% |
| 2010 Q3 | 25.35 Million TWD | 37.63% |
| 2010 Q2 | 18.42 Million TWD | 94.77% |
| 2010 Q1 | 9.45 Million TWD | 0.0% |
| 2010 Q4 | 23.59 Million TWD | -6.95% |
| 2010 FY | - TWD | -13.26% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Maxigen Biotech Inc. | 177.09 Million TWD | -127.394% |
| SciVision Biotech Inc. | 281.34 Million TWD | -43.132% |
| Bionime Corporation | 179.78 Million TWD | -123.994% |
| Pegavision Corporation | 2.91 Billion TWD | 86.2% |
| Visco Vision Inc. | 733.58 Million TWD | 45.106% |